CPP-115
Legal status
Legal status
  • Investigational
Identifiers
  • (1S,3S)-3-Amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC7H9F2NO2
Molar mass177.151 g·mol−1

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2][3] and Tourette syndrome.[4]

CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]

History

CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6][7]

CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]

As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]

References

  1. 1 2 Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, et al. (January 2012). "(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction". Journal of Medicinal Chemistry. 55 (1): 357–366. doi:10.1021/jm201231w. PMC 3257419. PMID 22128851.
  2. ↑ "Epilepsy Pipeline Tracker: CPP-115". epilepsy.com.
  3. ↑ Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O (2016). "A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms". Epilepsy & Behavior Case Reports. 6: 67–69. doi:10.1016/j.ebcr.2016.08.002. PMC 5024311. PMID 27668180.
  4. 1 2 "CPP-115". Adis Insight.
  5. ↑ Silverman RB (January 2012). "The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms". Journal of Medicinal Chemistry. 55 (2): 567–575. doi:10.1021/jm201650r. PMC 3266980. PMID 22168767.
  6. ↑ Hawker DD, Silverman RB (October 2012). "Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase". Bioorganic & Medicinal Chemistry. 20 (19): 5763–5773. doi:10.1016/j.bmc.2012.08.009. PMC 3448830. PMID 22944334.
  7. ↑ Bandell B (August 31, 2009). "Catalyst Pharmaceutical signs licensing deal with Northwestern". South Florida Business Journal.
  8. ↑ "Catalyst Pharmaceuticals Expands Commercial Leadership Team" (Press release). Catalyst Pharmaceuticals.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.